Trial Profile
A Maintenance Study Evaluating the Long Term Safety of XL184 in Subjects with Advanced Malignancies Previously Enrolled in Other XL184 Studies
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 18 Dec 2013
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 15 Aug 2013 Status changed from recruiting to active, no longer recruiting, according to M.D. Anderson record reporting closed to recruitment.
- 20 Jul 2012 New trial record